Review Article
Porcine to Human Heart Transplantation: Is Clinical Application Now Appropriate?
Table 1
The longest (median) reported heterotopic cardiac xenograft survival as a function of donor genetics and immune suppression.
| |||||||||||||||||||||||||||||||||||||||||||||||||
n.r.: none reported. §Soluble CR1 to block complement activation. ‡Cobra venom factor at 0.25–0.5 mg/kg prior to surgery and 0.1–0.5 mg/kg every 1–4 days thereafter. Included use of alpha-Gal polymer GAS914 [127] or Nex1285 [128]. †Immune suppression included anti-CD20 (Rituximab) B-cell depletion. ΔhDAF (human CD55) minigene [129]. ∇A murine H-2Kb regulated human CD55 transgene [77]. #hCD46 transgene based on 60 kb human genomic CD46 DNA [130]. ¶hCD46 transgene based on a human CD46 minigene [131]. |